cashed up, ready to make medical history, page-17

Jamwolf, appreciate your comments. However the ONLY reason the shareprice has been so low over the last few years is because of lack of funds. We have seen all the US based RNAi companies go up in the 1000s of percents, despite many of them having inferior technology. Alnylam is a $6.5b company. They have nothing close to commercialisation. ddRNAi will be just as validated THIS YEAR, and BLT own all the core patents. Not only that, we are not dealing in the orphan diseases category.

The brakes are off.